retarded behavior and low motor activity 4, 25 , although this response was not observed by other researchers 12 .
In another line of investigation there has been an increasing number of papers showing that total 3,13,17 0 r selective REM SD 26-28 brings a significant, although transitory, improvement to depressed patients.
These data led us to study the effects of one night of total SD on patients with PD.
MATERIAL AND METHODS
Patients -Twelve parkinsonian patients were included in the experiment. Diagnosis of PD was based on the presence of at least three clinical signs: bradykinesia, rigidity and posture and gait disturbances. All the volunteers had a diagnosis of idiophatic PD, age ranging from 40 to 70 years, and a score for parkinsonian syndrome from 20 to 50% by the New York University Parkinson's disease evaluation form (NYU form) (15) .
No patient had history of any other neurological disorder, previous exposition to manganese, neuroleptics and other drugs known to induce parkinsonian syndrome. All patients signed an informed consent, after being explained in details about the experimental protocol, care being taken in order to avoid describing the expected therapeutic effect, so that an undesired placebo effect was avoided.
Procedure -After admission to the protocol, the patients were maintained for at least two weeks with their medication unchanged. They were then admitted to a special ward at the Medical School Hospital, where they had contact only with the research staff.
The admittance day was considered day 0. At 5:00 PM the patients were evaluated using the Hamilton Rating Scale for Depression (HRSD) (-">) followed by the NYU form. The patients were instructed to go to bed on that evening and to awake in the next morning at their usual time. The patients remained all day 1 in the Hospital and at 5:00 PM they were again evaluated using both rating scales. At 9:00 PM the patients were removed to an isolated Clinical Research Unit to spend the night awaken. The Unit was composed by a visiting room and a bathroom, with a TV set, ambiental music and game sets (like chess and playing cards). Patients were instructed not to drink coffee or other stimulant beverages and not to smoke. The procedure was done with groups of 2 or 3 patients under close supervision of 2 members of our staff. At morning of day 2 the patients returned to the special ward and at 10:00 AM were evaluated by the NYU form (except appendix 6). At 5:00 PM they were evaluated again using both rating scales. After that they were, discharged, with instructions to return at 5:00 PM on day 8, 15 and 29 when both rating scales were again applied. The rating scales were applied by an independent researcher who was beforehand aware of the protocol conditions, that is, the experiment was not run blind, because of its own peculiarities. In fact, in the first phase of the clinical interview the patients spontaneously reported his previous sleep deprivation. On the other hand, video taped examinations would not be applicable taking into consideration all the items of the NYU form.
The HRSD was modified so that items 7 (work and activities), 9 (agitation), 13 (general somatic symptoms) were excluded as to cope with disability of the patients.
Item 17 (insight) was also excluded as the PD patients have a clear insight of their own disease. Therefore the maximum score for the remaining 13 items was 40 points, instead of the original 53. The NYU form was applied according to the author's instructions (J5).
Results were analysed by comparing the scores at day 0 (afternoon of admission) with data obtained at day 1 (after a night sleep in the Hospital), to verify the possible influence of hospitalization on symptomatology of PD, using the Friedman test.
Using the same test, a comparison was done of the data obtained at day 0 (afternoon before deprivation) with data collected at days 2, 8, 15 and 29, so that it was possible to assess the influence of sleep deprivation on the clinical picture of PD. Table 1 summarizes personal data of the 12 patients. They were in average 61 years old, with a median disease duration of 5.1 years. All were under medication, either anticholinergics (patients 1, 2, 8 and 12) or L-Dopa (patients 3, 9, 10 and  11) or the combination of both drugs. Comparing the total scores for both rating scales days 0 and 1 disclosed no statistical significant differences, indicating that hospitalization did not influence the symptomatology of PD (TabTe 2).
RESULTS
Comparison of day 0 with days 2, 8, 15 and 29, however, disclosed statisticaly significant results. As it can be seen, values at day 0 differ significantly from 2, 8, 15 for rigidity, bradykinesia, gait and posture disturbances and functional disability evaluation. On day 29 these variables showed values still lower than those seen at day 0, although the differences did not reach statistical significance. As also seen in Table 2 , tremor was not influenced by SD, as the scores after SD did not significantly differ from values obtained at day 0. It must be stressed that 5 patients did not display tremor in their symptomatology, therefore the data on Table 2 are from the remaining 7 patients. Abnormal involuntary movements (NTU form appendix 5) were not taken into account as only 3 of the patients had such movements and statistical data based on such small population would be meaningless. It was noted that these 3 patients had an increase of their involuntary movements on the day after SD, although they claimed it was easier to walk and to use the hands. Aside from the clear improvement detected by the NTU form items, the examiners had a subjective impression that the patients displayed an overall better functional ability on the day following SD. Such impression was confirmed by the reports of the patients and their relatives. For example, patient 1 was taken to the Clinical Research Unit on a wheelchair, and on the day after SD was able to walk unaided; patient 10, who needed support to walk before SD, after it was able to walk alone, although there was a clear worsening of the involuntary movements induced by L-Dopa. Figure 1 shows the effect of SD on depressive symptoms and on the general score for PD. Improvement of parkinsonian symptoms remained for 2 weeks, while depressive symptoms at day 15 were no longer significant from day 0. 
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